Increased expression of Toll-like receptors 7 and 9 in myasthenia gravis thymus characterized by active Epstein-Barr virus infection.

[1]  Martin Schwemmle,et al.  Mx GTPases: dynamin-like antiviral machines of innate immunity. , 2015, Trends in microbiology.

[2]  Toshiyuki Shimizu,et al.  Targeting cell surface TLR7 for therapeutic intervention in autoimmune diseases , 2015, Nature Communications.

[3]  S. Akira,et al.  B Cell–Intrinsic TLR7 Signaling Is Essential for the Development of Spontaneous Germinal Centers , 2014, The Journal of Immunology.

[4]  S. Berrih-Aknin,et al.  Myasthenia gravis: a comprehensive review of immune dysregulation and etiological mechanisms. , 2014, Journal of autoimmunity.

[5]  S. Franzi,et al.  Innate immunity in myasthenia gravis thymus: pathogenic effects of Toll-like receptor 4 signaling on autoimmunity. , 2014, Journal of autoimmunity.

[6]  S. Sacre,et al.  Emerging Role of Endosomal Toll-Like Receptors in Rheumatoid Arthritis , 2013, Front. Immunol..

[7]  S. Berrih-Aknin,et al.  Autoimmune myasthenia gravis: autoantibody mechanisms and new developments on immune regulation , 2013, Current opinion in neurology.

[8]  F. Paul,et al.  Multiple Sclerosis: Modulation of Toll-Like Receptor (TLR) Expression by Interferon-β Includes Upregulation of TLR7 in Plasmacytoid Dendritic Cells , 2013, PloS one.

[9]  R. Mantegazza,et al.  Etiology of myasthenia gravis: innate immunity signature in pathological thymus. , 2013, Autoimmunity reviews.

[10]  R. Lisak,et al.  Ectopic germinal centers, BAFF and anti-B-cell therapy in myasthenia gravis. , 2013, Autoimmunity reviews.

[11]  E. Fadel,et al.  Implication of double‐stranded RNA signaling in the etiology of autoimmune myasthenia gravis , 2013, Annals of neurology.

[12]  E. Coccia,et al.  EBV stimulates TLR‐ and autophagy‐dependent pathways and impairs maturation in plasmacytoid dendritic cells: Implications for viral immune escape , 2013, European journal of immunology.

[13]  Zhaolin Hua,et al.  TLR signaling in B-cell development and activation , 2012, Cellular and Molecular Immunology.

[14]  S. Marino,et al.  Targeting Toll-like receptors: Emerging therapeutics for multiple sclerosis management , 2011, Journal of Neuroimmunology.

[15]  R. Mantegazza,et al.  The thymus in myasthenia gravis: Site of “innate autoimmunity”? , 2011, Muscle & nerve.

[16]  R. Mantegazza,et al.  Inflammation and Epstein-Barr Virus Infection Are Common Features of Myasthenia Gravis Thymus: Possible Roles in Pathogenesis , 2011, Autoimmune diseases.

[17]  S. Ning,et al.  Innate immune modulation in EBV infection , 2011, Herpesviridae.

[18]  K. Takada,et al.  TLR9 Contributes to the Recognition of EBV by Primary Monocytes and Plasmacytoid Dendritic Cells , 2010, The Journal of Immunology.

[19]  S. Akira,et al.  Critical role of TLR7 in the acceleration of systemic lupus erythematosus in TLR9-deficient mice. , 2010, Journal of autoimmunity.

[20]  S. Akira,et al.  The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors , 2010, Nature Immunology.

[21]  D. Fitzgerald,et al.  The TLR7 agonist, imiquimod, increases IFN-β production and reduces the severity of experimental autoimmune encephalomyelitis , 2010, Journal of Neuroimmunology.

[22]  Andrew E. Parker,et al.  Targeting Toll-like receptors: emerging therapeutics? , 2010, Nature Reviews Drug Discovery.

[23]  W. Hammerschmidt,et al.  Toll-Like Receptor Agonists Synergistically Increase Proliferation and Activation of B Cells by Epstein-Barr Virus , 2010, Journal of Virology.

[24]  S. Crampton,et al.  Innate pathways to B‐cell activation and tolerance , 2010, Annals of the New York Academy of Sciences.

[25]  S. Izui,et al.  Emerging roles of TLR7 and TLR9 in murine SLE. , 2009, Journal of autoimmunity.

[26]  R. Mantegazza,et al.  Epstein‐Barr virus persistence and reactivation in myasthenia gravis thymus , 2009, Annals of neurology.

[27]  J. Lünemann,et al.  Antiviral immune responses: triggers of or triggered by autoimmunity? , 2009, Nature Reviews Immunology.

[28]  S. Berrih-Aknin,et al.  Thymus and Myasthenia Gravis: What can we learn from DNA microarrays? , 2008, Journal of Neuroimmunology.

[29]  H. Shiono,et al.  The myasthenia gravis thymus: A rare source of human autoantibody-secreting plasma cells for testing potential therapeutics , 2008, Journal of Neuroimmunology.

[30]  P. V. van Riel,et al.  Type I interferons might form the link between Toll-like receptor (TLR) 3/7 and TLR4-mediated synovial inflammation in rheumatoid arthritis (RA) , 2008, Annals of the rheumatic diseases.

[31]  Antonio Martínez,et al.  Expression of the Interferon Regulatory Factor 8/ICSBP-1 in Human Reactive Lymphoid Tissues and B-cell Lymphomas: A Novel Germinal Center Marker , 2008, The American journal of surgical pathology.

[32]  P. Fisher,et al.  Central role of interferon regulatory factor‐1 (IRF‐1) in controlling retinoic acid inducible gene‐I (RIG‐I) expression , 2007, Journal of cellular physiology.

[33]  D. Walls,et al.  Manipulation of the Toll-Like Receptor 7 Signaling Pathway by Epstein-Barr Virus , 2007, Journal of Virology.

[34]  S. Akira,et al.  Toll-like Receptors and Type I Interferons* , 2007, Journal of Biological Chemistry.

[35]  E. Coccia,et al.  Sensitization to TLR7 Agonist in IFN-β-Preactivated Dendritic Cells1 , 2007, The Journal of Immunology.

[36]  R. Longnecker,et al.  Epstein-Barr virus latent membrane protein 2A and autoimmunity. , 2007, Trends in immunology.

[37]  A. Marshak‐Rothstein.  Toll-like receptors in systemic autoimmune disease , 2006, Nature Reviews Immunology.

[38]  R. Tisch,et al.  EBV Latent Membrane Protein 2A Induces Autoreactive B Cell Activation and TLR Hypersensitivity1 , 2006, The Journal of Immunology.

[39]  A. Lanzavecchia,et al.  Toll‐like receptor stimulation as a third signal required for activation of human naive B cells , 2006, European journal of immunology.

[40]  B. Becher,et al.  Innate immunity mediated by TLR9 modulates pathogenicity in an animal model of multiple sclerosis. , 2006, The Journal of clinical investigation.

[41]  P. Lipsky,et al.  Regulation of the germinal center gene program by interferon (IFN) regulatory factor 8/IFN consensus sequence-binding protein , 2006, The Journal of experimental medicine.

[42]  L. Joosten,et al.  The expression of toll-like receptors 3 and 7 in rheumatoid arthritis synovium is increased and costimulation of toll-like receptors 3, 4, and 7/8 results in synergistic cytokine production by dendritic cells. , 2005, Arthritis and rheumatism.

[43]  E. Arnoldi,et al.  Increased toll-like receptor 4 expression in thymus of myasthenic patients with thymitis and thymic involution. , 2005, The American journal of pathology.

[44]  G. Cheng,et al.  The host type I interferon response to viral and bacterial infections , 2005, Cell Research.

[45]  A. Iwasaki,et al.  Toll-like receptor control of the adaptive immune responses , 2004, Nature Immunology.

[46]  Y. Richard,et al.  Thymic B cells from myasthenia gravis patients are activated B cells. Phenotypic and functional analysis. , 1990, Journal of immunology.

[47]  J. Newsom-Davis,et al.  Myasthenic thymus and thymoma are selectively enriched in acetylcholine receptor–reactive T cells , 1990, Annals of neurology.

[48]  J. Minárovits,et al.  Epigenetic dysregulation of epstein-barr virus latency and development of autoimmune disease. , 2011, Advances in experimental medicine and biology.

[49]  P. von Landenberg,et al.  Toll-like receptors and autoimmunity. , 2008, Autoimmunity reviews.

[50]  E. Coccia,et al.  Sensitization to TLR7 agonist in IFN-beta-preactivated dendritic cells. , 2007, Journal of immunology.